Dr. Bordonaro on the Treatment of Advanced CRC | OncLive

Dr. Bordonaro on the Treatment of Advanced CRC

March 13, 2014

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Bordonaro says the only choice for patients who have RAS wild-type disease and fail on oxaliplatin- and irinotecan-based chemotherapy is panitumumab. However, this therapy cannot be used if the patient received panitumumab plus oxaliplatin-based chemotherapy in the first-line setting.

The only option for patients who have received prior panitumumab therapy is regorafenib, Bordonaro says. This recomendation is based on the recent data of the CORRECT trial, a phase III study that tested the efficacy of regorafenib in comparison to placebo in patients in the third-line.


x